Acquired Defects in CFTR-dependent β-adrenergic Sweat Secretion in Chronic Obstructive Pulmonary Disease
Overview
Affiliations
Rationale: Smoking-induced chronic obstructive pulmonary disease (COPD) is associated with acquired systemic cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. Recently, sweat evaporimetry has been shown to efficiently measure β-adrenergic sweat rate and specifically quantify CFTR function in the secretory coil of the sweat gland.
Objectives: To evaluate the presence and severity of systemic CFTR dysfunction in smoking-related lung disease using sweat evaporimetry to determine CFTR-dependent sweat rate.
Methods: We recruited a cohort of patients consisting of healthy never smokers (N = 18), healthy smokers (12), COPD smokers (25), and COPD former smokers (12) and measured β-adrenergic sweat secretion rate with evaporative water loss, sweat chloride, and clinical data (spirometry and symptom questionnaires).
Measurements And Main Results: β-adrenergic sweat rate was reduced in COPD smokers (41.9 ± 3.4, P < 0.05, ± SEM) and COPD former smokers (39.0 ± 5.4, P < 0.05) compared to healthy controls (53.6 ± 3.4). Similarly, sweat chloride was significantly greater in COPD smokers (32.8 ± 3.3, P < 0.01) and COPD former smokers (37.8 ± 6.0, P < 0.01) vs. healthy controls (19.1 ± 2.5). Univariate analysis revealed a significant association between β-adrenergic sweat rate and female gender (β = 0.26), age (-0.28), FEV1% (0.35), dyspnea (-0.3), and history of smoking (-0.27; each P < 0.05). Stepwise multivariate regression included gender (0.39) and COPD (-0.43) in the final model (R()2 = 0.266, P < 0.0001).
Conclusions: β-adrenergic sweat rate was significantly reduced in COPD patients, regardless of smoking status, reflecting acquired CFTR dysfunction and abnormal gland secretion in the skin that can persist despite smoking cessation. β-adrenergic sweat rate and sweat chloride are associated with COPD severity and clinical symptoms, supporting the hypothesis that CFTR decrements have a causative role in COPD pathogenesis.
Caohuy H, Eidelman O, Chen T, Mungunsukh O, Yang Q, Walton N Sci Rep. 2024; 14(1):16895.
PMID: 39043712 PMC: 11266487. DOI: 10.1038/s41598-024-66473-4.
Baker E, Harris W, Guimbellot J, Bliton K, Rowe S, Raju S J Cyst Fibros. 2024; 23(5):959-966.
PMID: 39033068 PMC: 11410542. DOI: 10.1016/j.jcf.2024.07.010.
Luettich K, Sharma M, Yepiskoposyan H, Breheny D, Lowe F Front Toxicol. 2022; 3:750254.
PMID: 35295103 PMC: 8915806. DOI: 10.3389/ftox.2021.750254.
Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.
Kaza N, Lin V, Stanford D, Hussain S, Libby E, Kim H Eur Respir J. 2021; 60(1).
PMID: 34916262 PMC: 10079430. DOI: 10.1183/13993003.01581-2021.
Carrasco-Hernandez L, Quintana-Gallego E, Calero C, Reinoso-Arija R, Ruiz-Duque B, Lopez-Campos J Biomedicines. 2021; 9(10).
PMID: 34680554 PMC: 8533244. DOI: 10.3390/biomedicines9101437.